📰 Toby Maher News
Page 2 - Toby Maher News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Toby Maher. Real-time updates on events, politics, business and more.
May 30, 2023
/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral...
May 23, 2023
Vicore Pharma’s drug candidate, C21 formulation, currently in a phase 2a trial aimed at people with idiopathic pulmonary fibrosis (IPF), has been patented.
May 22, 2023
Nalbuphine ER resulted in a rapid and marked reduction in recorded daytime cough among patients suffering from IPF-related cough The mean change in 24-hour objective cough frequency was similar in... | May 22, 2023
May 19, 2023
Here's a deep dive into a packed round 5 in the Central Highlands Football League. There are two...
May 19, 2023
Here's a deep dive into a packed round 5 in the Central Highlands Football League. There are two...
May 17, 2023
The phase 3 clinical trials evaluating ziritaxestat for treating idiopathic pulmonary fibrosis showed no improvement in clinical outcomes leading to the termination of the trials due to lack of efficacy.
May 2, 2023
/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral...
May 1, 2023
Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care reduced FVC decline by 80% relative... | April 30, 2023
April 30, 2023
Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care...
April 30, 2023
Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care reduced FVC decline by 80% relative... | April 30, 2023